Aspira Women's Health Inc. (AWH)
USD 0.77
(1.97%)
USD 0.77
(1.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.69 Million USD | 22.64% |
| 2022 | -21.57 Million USD | 31.96% |
| 2021 | -31.71 Million USD | -79.86% |
| 2020 | -17.63 Million USD | -18.76% |
| 2019 | -14.84 Million USD | -30.55% |
| 2018 | -11.37 Million USD | -8.33% |
| 2017 | -10.49 Million USD | 29.87% |
| 2016 | -14.96 Million USD | 21.7% |
| 2015 | -19.11 Million USD | 0.49% |
| 2014 | -19.2 Million USD | -117.81% |
| 2013 | -8.81 Million USD | -23.41% |
| 2012 | -7.14 Million USD | 59.83% |
| 2011 | -17.79 Million USD | 6.54% |
| 2010 | -19.03 Million USD | 13.67% |
| 2009 | -22.04 Million USD | -20.28% |
| 2008 | -18.33 Million USD | 13.87% |
| 2007 | -21.28 Million USD | 3.55% |
| 2006 | -22.06 Million USD | 37.72% |
| 2005 | -35.43 Million USD | -78.58% |
| 2004 | -19.84 Million USD | 46.01% |
| 2003 | -36.74 Million USD | -26.4% |
| 2002 | -29.07 Million USD | -12.63% |
| 2001 | -25.81 Million USD | -27.13% |
| 2000 | -20.3 Million USD | -152.35% |
| 1999 | -8.04 Million USD | 0.07% |
| 1998 | -8.05 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.53 Million USD | 23.74% |
| 2024 Q1 | -4.62 Million USD | -49.85% |
| 2023 Q3 | -4.7 Million USD | -103.11% |
| 2023 Q1 | -6.33 Million USD | -36.47% |
| 2023 FY | -16.69 Million USD | 22.64% |
| 2023 Q2 | -2.31 Million USD | 63.45% |
| 2023 Q4 | -3.08 Million USD | 34.36% |
| 2022 Q3 | -4.55 Million USD | 44.86% |
| 2022 Q2 | -8.26 Million USD | 11.01% |
| 2022 Q1 | -9.28 Million USD | -3.66% |
| 2022 FY | -21.57 Million USD | 31.96% |
| 2022 Q4 | -4.64 Million USD | -1.91% |
| 2021 Q3 | -9.7 Million USD | -37.22% |
| 2021 Q1 | -5.92 Million USD | 2.65% |
| 2021 Q4 | -8.96 Million USD | 7.69% |
| 2021 Q2 | -7.07 Million USD | -19.49% |
| 2021 FY | -31.71 Million USD | -79.86% |
| 2020 Q3 | -4.28 Million USD | -11.9% |
| 2020 Q2 | -3.83 Million USD | -3.37% |
| 2020 FY | -17.63 Million USD | -18.76% |
| 2020 Q1 | -3.7 Million USD | -9.42% |
| 2020 Q4 | -6.08 Million USD | -41.85% |
| 2019 Q3 | -3.82 Million USD | 11.45% |
| 2019 FY | -14.84 Million USD | -30.55% |
| 2019 Q2 | -4.31 Million USD | -16.09% |
| 2019 Q1 | -3.71 Million USD | -31.77% |
| 2019 Q4 | -3.38 Million USD | 11.34% |
| 2018 Q3 | -2.65 Million USD | 13.02% |
| 2018 Q4 | -2.82 Million USD | -6.33% |
| 2018 FY | -11.37 Million USD | -8.33% |
| 2018 Q1 | -2.85 Million USD | 3.55% |
| 2018 Q2 | -3.04 Million USD | -6.98% |
| 2017 Q3 | -2.5 Million USD | -6.31% |
| 2017 Q2 | -2.36 Million USD | 11.71% |
| 2017 Q1 | -2.67 Million USD | 6.08% |
| 2017 FY | -10.49 Million USD | 29.87% |
| 2017 Q4 | -2.95 Million USD | -17.78% |
| 2016 Q3 | -3.47 Million USD | 7.28% |
| 2016 Q1 | -4.89 Million USD | 1.73% |
| 2016 Q2 | -3.74 Million USD | 23.44% |
| 2016 Q4 | -2.84 Million USD | 18.12% |
| 2016 FY | -14.96 Million USD | 21.7% |
| 2015 FY | -19.11 Million USD | 0.49% |
| 2015 Q4 | -4.98 Million USD | 3.17% |
| 2015 Q3 | -5.14 Million USD | -6.12% |
| 2015 Q2 | -4.84 Million USD | -17.21% |
| 2015 Q1 | -4.13 Million USD | -1.5% |
| 2014 Q2 | -5.55 Million USD | -39.33% |
| 2014 Q3 | -5.59 Million USD | -0.65% |
| 2014 FY | -19.2 Million USD | -117.81% |
| 2014 Q4 | -4.07 Million USD | 27.1% |
| 2014 Q1 | -3.98 Million USD | -119.43% |
| 2013 Q1 | -2.57 Million USD | -86.98% |
| 2013 Q3 | -2.31 Million USD | -9.31% |
| 2013 Q2 | -2.11 Million USD | 17.66% |
| 2013 Q4 | -1.81 Million USD | 21.48% |
| 2013 FY | -8.81 Million USD | -23.41% |
| 2012 Q4 | -1.37 Million USD | 31.96% |
| 2012 Q2 | -1.97 Million USD | -11.15% |
| 2012 FY | -7.14 Million USD | 59.83% |
| 2012 Q1 | -1.77 Million USD | 43.35% |
| 2012 Q3 | -2.02 Million USD | -2.38% |
| 2011 Q4 | -3.13 Million USD | 32.6% |
| 2011 Q1 | -4.29 Million USD | -6.9% |
| 2011 Q3 | -4.65 Million USD | 18.59% |
| 2011 Q2 | -5.71 Million USD | -33.14% |
| 2011 FY | -17.79 Million USD | 6.54% |
| 2010 Q4 | -4.01 Million USD | -46.71% |
| 2010 Q3 | -2.73 Million USD | -291.98% |
| 2010 Q2 | -698 Thousand USD | 93.98% |
| 2010 Q1 | -11.58 Million USD | -80.33% |
| 2010 FY | -19.03 Million USD | 13.67% |
| 2009 Q3 | -11.01 Million USD | -514.33% |
| 2009 FY | -22.04 Million USD | -20.28% |
| 2009 Q4 | -6.42 Million USD | 41.67% |
| 2009 Q2 | -1.79 Million USD | 36.31% |
| 2009 Q1 | -2.81 Million USD | 34.21% |
| 2008 Q1 | -4.84 Million USD | -47.21% |
| 2008 FY | -18.33 Million USD | 13.87% |
| 2008 Q2 | -4.46 Million USD | 7.94% |
| 2008 Q3 | -4.74 Million USD | -6.34% |
| 2008 Q4 | -4.27 Million USD | 9.8% |
| 2007 Q2 | -6.82 Million USD | -12.88% |
| 2007 Q1 | -6.04 Million USD | -226.69% |
| 2007 FY | -21.28 Million USD | 3.55% |
| 2007 Q4 | -3.29 Million USD | 35.67% |
| 2007 Q3 | -5.11 Million USD | 25.04% |
| 2006 Q2 | -7.73 Million USD | -41.56% |
| 2006 Q1 | -5.46 Million USD | 40.8% |
| 2006 Q3 | -7.01 Million USD | 9.3% |
| 2006 Q4 | -1.85 Million USD | 73.62% |
| 2006 FY | -22.06 Million USD | 37.72% |
| 2005 FY | -35.43 Million USD | -78.58% |
| 2005 Q1 | -9.33 Million USD | -190.51% |
| 2005 Q3 | -7.47 Million USD | 17.31% |
| 2005 Q4 | -9.23 Million USD | -23.46% |
| 2005 Q2 | -9.04 Million USD | 3.12% |
| 2004 Q2 | -13.14 Million USD | -75.67% |
| 2004 Q1 | -7.48 Million USD | -11.51% |
| 2004 Q3 | -9.52 Million USD | 27.49% |
| 2004 FY | -19.84 Million USD | 46.01% |
| 2004 Q4 | 10.31 Million USD | 208.21% |
| 2003 Q2 | -15.6 Million USD | -69.69% |
| 2003 Q4 | -6.7 Million USD | -28.11% |
| 2003 Q1 | -9.19 Million USD | -37.15% |
| 2003 Q3 | -5.23 Million USD | 66.44% |
| 2003 FY | -36.74 Million USD | -26.4% |
| 2002 Q3 | -7.9 Million USD | -8.36% |
| 2002 Q4 | -6.7 Million USD | 15.2% |
| 2002 FY | -29.07 Million USD | -12.63% |
| 2002 Q1 | -7.16 Million USD | -0.92% |
| 2002 Q2 | -7.29 Million USD | -1.87% |
| 2001 Q1 | -5.98 Million USD | -21.55% |
| 2001 FY | -25.81 Million USD | -27.13% |
| 2001 Q4 | -7.09 Million USD | -2.63% |
| 2001 Q3 | -6.91 Million USD | -18.95% |
| 2001 Q2 | -5.81 Million USD | 2.84% |
| 2000 Q1 | -4.6 Million USD | 0.0% |
| 2000 Q2 | -4.6 Million USD | -0.02% |
| 2000 Q4 | -4.92 Million USD | 20.22% |
| 2000 Q3 | -6.17 Million USD | -34.01% |
| 2000 FY | -20.3 Million USD | -152.35% |
| 1999 FY | -8.04 Million USD | 0.07% |
| 1998 FY | -8.05 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 92.821% |
| Prenetics Global Limited | -62.72 Million USD | 73.391% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -978.165% |
| CareDx, Inc | -190.28 Million USD | 91.229% |
| Exact Sciences Corporation | -204.14 Million USD | 91.825% |
| Exagen Inc. | -23.68 Million USD | 29.545% |
| Inotiv, Inc. | -105.14 Million USD | 84.126% |
| Guardant Health, Inc. | -479.44 Million USD | 96.519% |
| Biodesix, Inc. | -52.14 Million USD | 67.994% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -534.832% |
| Precipio, Inc. | -5.85 Million USD | -185.153% |
| iSpecimen Inc. | -11.09 Million USD | -50.367% |
| Natera, Inc. | -434.8 Million USD | 96.161% |
| Standard BioTools Inc. | -74.65 Million USD | 77.644% |
| 23andMe Holding Co. | -666.7 Million USD | 97.497% |
| Castle Biosciences, Inc. | -57.46 Million USD | 70.957% |
| Personalis, Inc. | -108.29 Million USD | 84.589% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 81.137% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -67.788% |
| OpGen, Inc. | -32.66 Million USD | 48.911% |
| T2 Biosystems, Inc. | -50.07 Million USD | 66.671% |
| Myriad Genetics, Inc. | -112 Million USD | 85.098% |
| ICON Public Limited Company | 612.33 Million USD | 102.726% |
| NeoGenomics, Inc. | -87.96 Million USD | 81.027% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -978.165% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 101.975% |
| RadNet, Inc. | 3.04 Million USD | 648.292% |
| MDxHealth SA | -43.1 Million USD | 61.276% |
| Psychemedics Corporation | -4.15 Million USD | -301.781% |
| Illumina, Inc. | -1.16 Billion USD | 98.562% |
| Check-Cap Ltd. | -17.56 Million USD | 4.998% |
| Twist Bioscience Corporation | -208.72 Million USD | 92.004% |
| DarioHealth Corp. | -59.42 Million USD | 71.915% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 90.055% |
| Sera Prognostics, Inc. | -36.24 Million USD | 53.948% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -65.9% |
| OPKO Health, Inc. | -188.86 Million USD | 91.163% |
| Medpace Holdings, Inc. | 282.81 Million USD | 105.901% |
| Neogen Corporation | -9.42 Million USD | -77.157% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -64.324% |
| Prenetics Global Limited | -62.72 Million USD | 73.391% |
| Mainz Biomed B.V. | -26.29 Million USD | 36.53% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -110.281% |
| Trinity Biotech plc | -24.01 Million USD | 30.51% |
| Neuronetics, Inc. | -30.18 Million USD | 44.715% |
| Sotera Health Company | 51.37 Million USD | 132.486% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -110.281% |